Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | LOX | P28300 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762519 | 1.00 | KMT2A (0.59) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL24435015 | 1.00 | KMT2A (0.59) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL3579235 | 0.96 | NPC1 (0.57) | KMT2APDK2NPC1LOXRAB9A | |
| SCHEMBL3579233 | 0.96 | NPC1 (0.57) | KMT2APDK2NPC1LOXRAB9A | |
| SCHEMBL13709423 | 0.92 | PDK2 (0.56) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL7068414 | 0.91 | KMT2A (0.62) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL2769546 | 0.91 | KMT2A (0.62) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL10721062 | 0.88 | KMT2A (0.60) | KMT2APDK2NPC1ALDH1A1RAB9A | |
| SCHEMBL8633268 | 0.87 | CNR1 (0.50) | KMT2APDK2NPC1LOXACE | |
| SCHEMBL6172949 | 0.86 | NPC1 (0.53) | KMT2APDK2NPC1LOXALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102216279-B | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI Co.,Ltd. (CN) | 2014-10-29 | — | — | CN | claimed |
| US-20250188032-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | BNH RESEARCH CO., LTD. (KR) | 2025-06-12 | — | — | US | disclosed |
| EP-4501910-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | BNH Research Co., Ltd. (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-119255981-A | Nitrogen-containing heterocyclic compound and use thereof | BNH研究有限责任公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-111333627-B | Substituted 2-hydro-pyrazole derivatives as anticancer agents | 正大天晴药业集团股份有限公司 | 2024-09-13 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023191468-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | 주식회사 비엔에이치리서치 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-9969719-B2 | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-05-15 | — | — | US | disclosed |
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| CN-107428731-A | Substituted 2-hydro-pyrazole derivatives as anti-cancer agents | 正大天晴药业集团股份有限公司 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017134555-A1 | DERIVATIVES OF PYRROLOIMIDAZOLE OR ANALOGUES THEREOF WHICH ARE USEFUL FOR THE TREATMENT OF INTER ALIA CANCER | EMCURE PHARMACEUTICALS LIMITED (IN) | 2017-08-10 | — | — | WO | disclosed |
| WO-2016141881-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | 南京明德新药研发股份有限公司 | 2016-09-15 | — | — | WO | disclosed |
| CN-102216279-B | Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI Co.,Ltd. (CN) | 2014-10-29 | — | — | CN | disclosed |
| US-5051444-A | Pyrrolidine derivatives as anti-amnesia agents | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1991-09-24 | — | — | US | disclosed |
| US-4880827-A | Pyrrolidine derivatives having inhibitory action for proline specific endopepidase | SUMITOMO PHARMACEUTICALS COMPANY, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0238319-A1 | Pyrrolidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072707-A1 | SUBSTITUTED 2-HYDROGEN-PYRAZOLE DERIVATIVE SERVING AS ANTICANCER DRUG | CDK4, CDK6, CDK3 | KMT2A 513/4885PDK2 53/4885NPC1 3516/4885 |
| US-20250188032-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND USES THEREOF | NLN, GRIN1, GRIN2A | KMT2A 687/4885PDK2 940/4885NPC1 847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.